Open AccessOpportunities for improving cardiovascular health outcomes in adults younger than 65 years with guideline‐recommended statin therapy
Author(s) -
Sarasua Sara M.,
Li Jiexiang,
Hernandez German T.,
Ferdinand Keith C.,
Tobin Jonathan N.,
Fiscella Kevin A.,
Jones Daniel W.,
Sinopoli Angelo,
Egan Brent M.
Publication year - 2017
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.13004
Subject(s) - medicine , statin , guideline , logistic regression , health care , physical therapy , pathology , economics , economic growth
The impact of age, race/ethnicity, healthcare insurance, and selected clinical variables on statin‐preventable ASCVD were quantified in adults aged 21 to 79 years from National Health and Nutrition Examination Surveys 2007–2012 using the 2013 American College of Cardiology/American Heart Association guideline on the treatment of cholesterol. Among ≈42.4 million statin‐eligible, untreated adults, 52.6% were hypertensive and 71% were younger than 65 years. Of ≈232 000 statin‐preventable ASCVD events annually, most occur in individuals younger than 65 years, with higher proportions in blacks and Hispanics than whites (73.0% and 69.2% vs 56.9%, respectively; P <.01). Among adults younger than 65 years, the ratio of statin‐eligible but untreated to statin‐treated adults was higher in blacks and Hispanics than whites (3.0 and 2.9 vs 1.3, respectively; P <.01), and blacks, men, hypertensives, and cigarette smokers were more likely to be statin eligible than their statin‐ineligible counterparts by multivariable logistic regression. Two thirds of untreated statin‐eligible adults had two or more healthcare visits per year. Identifying and treating more statin‐eligible adults in the healthcare system could improve cardiovascular health equity.